Conduct of Studies to Evaluate the Cardiovascular Toxicity of an HIV Tricombo Therapy (ABC/DTG/3TC) ing Sprague Dawley Rats (F0 Dosed by Oral Gavage; F1 Exposed Perinatally)

该项目的目标是为转化毒理学司（DTT）的活动提供支持，这些活动旨在预防因接触化学或物理剂而引起的疾病或不良影响。该计划旨在评估早期接触化学品后的毒性。建议对包括孕妇在内的所有艾滋病毒阳性个体进行抗逆转录病毒治疗。Abacavir (ABC) /dolutegravir (DTG)/拉米夫定（3TC）是一种抗逆转录病毒治疗药物，该项目正在评估中，特别关注从妊娠第6天到F1后代断奶，以及另外3个月每天服用ABC/DTG/3TC的F0公鼠的潜在心血管毒性。F1后代将在围产期（妊娠期和哺乳期转移）暴露，但不直接给药。F1和F0动物将在几个时间点评估心脏功能参数，以确定ABC/DTG/3TC暴露是否会诱发心脏毒性。

The goal of this project is to provide support of the Division of Translational Toxicology (DTT) activities targeted toward the prevention of diseases or adverse effects caused by exposure to chemical or physical agents. This program is designed to evaluate toxicity following early life exposure to chemicals. Antiretroviral therapies (ART) are recommended for all HIV positive individuals including pregnant mothers. Abacavir (ABC) /dolutegravir (DTG)/lamivudine (3TC) is an ART under evaluation in the project with a specific focus on potential cardiovascular toxicity in F0 dams dosed daily with ABC/DTG/3TC from gestation day 6 through weaning of their F1 offspring, and for an additional 3 months. F1 offspring will be exposed perinatally (gestation and lactational transfer) but not directly dosed. Both F1 and F0 animals will be evaluated at several time points for functional cardiac parameters to determine if ABC/DTG/3TC exposure induces cardiotoxicity. Keywords: HIV/AIDS, Human immunodeficiency virus infection, acquired immune deficiency syndrome, primary HIV, acute retroviral syndrome, asymptomatic HIV, chronic HIV